Introduction
============

Cholestasis, defined as little or no bile flow from the liver into the intestine, is a complex pathologic condition that can develop from either functional etiologies, such as hepatic parenchymal disease secondary to hepatitis, or mechanical etiologies, such as an obstructing pancreatic cancer or biliary stricture. In the pediatric population, cholestasis resulting from prolonged parenteral nutrition is by far the most common etiology. Cholestatic injury has not only a hepatic component but also an intestinal one. Failure of the intestinal barrier with decreased intestinal resistance, increased bacterial translocation, and increased episodes of sepsis has been well described (Campillo et al. [@b10]; Pascual et al. [@b31]; Frances et al. [@b19]); however, the exact mechanisms remain poorly understood.

Common bile duct ligation (CBDL) is a standard model of cholestasis in the literature (Georgiev et al. [@b20]). CBDL in mice leads to both hepatic and intestinal injuries which are precisely interrelated. We have previously found differences in the systemic inflammatory responses and outcome following CBDL between two inbred mouse strains, C57BL/6J (B6) and A/J, suggesting a genetic contribution (Alaish et al. [@b1]). In particular, B6 mice were significantly more likely to develop ascites following 1 week of CBDL (Alaish et al. [@b1]). In concordance with this observation, the frequency of mortality after CBDL was significantly higher in B6 mice compared to A/J mice on days following CBDL (Alaish et al. [@b1]). Interestingly, although both strains demonstrated markedly elevated plasma liver function tests following CBDL, no difference was noted in liver histology between the two ligated strains. More recently, our laboratory has shown decreased intestinal resistance and increased bacterial translocation following CBDL in these same two strains of inbred mice. Furthermore, we found genetic variation in the intestinal resistance and bacterial translocation rates, which correlated with mortality following CBDL in different strains of inbred mice (Alaish et al. [@b2]). Further analysis implicated an IFN-γ-mediated apoptotic-independent mechanism of tight junction disruption, which has been well described in vitro (Madara and Stafford [@b29]; Marano et al. [@b30]; Youakim and Ahdieh [@b41]; Bruewer et al. [@b6]; Clayburgh et al. [@b11]), as a mechanism possibly responsible for the genetic variation. Nevertheless, the 2.5-fold changes in IFN-γ gene expression following CBDL, albeit significant, did not seem monumental enough to fully explain the striking genetic influence on mortality following CBDL in the mice. In order to uncover other potential mechanisms including novel pathways, we embarked on a whole-genome microarray analysis of jejunal tissue in these two different strains of inbred mice following either a sham operation or CBDL. The differentially expressed genes reported here constitute a resource of candidate genes for roles in cholestatic intestinal injury.

Material and Methods
====================

Animals
-------

Male A/J and C57BL/6J (B6) mice (8 weeks old) were obtained from the Jackson Laboratory (Bar Harbor, ME) and maintained in identical environmental conditions in a pathogen-free animal facility with 12-h light--dark cycles. All mice weighed 18--25 g at the time of operation. Matriptase (*St14*) hypomorphic C57BL/6J mice (List et al. [@b27]) were bred in the Antalis laboratory. Animal studies were conducted according to protocols reviewed and approved by the University of Maryland School of Medicine Institutional Animal Care and Use Committee and adhered to guidelines promulgated by the National Institutes of Health. In accordance with these guidelines, we used the minimum number of animals to meet the rigor necessary for this series of experiments.

Experimental design
-------------------

### CBDL operative procedure

Mice were anesthetized by inhaled isoflurane anesthesia. The abdomen was clipped and then prepared in sterile fashion with 70% ethyl-ethanol followed by betadine. A transverse upper abdominal incision was performed. The CBD was dissected away from the portal vein and was ligated near its junction with the duodenum using aneurysm clips engineered with a precisely standardized opening/closing mechanism. The abdominal wall was then closed in a two-layer fashion using absorbable sutures. Sham-operated mice were treated identically but without dissection or ligation of the CBD. Postoperatively, animals were resuscitated with warmed subcutaneous injections of saline (1 mL) to replace losses. Mice were returned to clean cages where food and water were provided ad libitum. Buprenorphine, 0.05--0.1 mg/kg was given subcutaneously at the time of surgery and then every 8--12 h to treat postoperative pain for 48--72 h.

### RNA extraction

Seven days following the surgery, the mice underwent deep general anesthesia and euthanasia by thoracotomy and cardiac exsanguination. Postoperative day 7 was chosen because this time point corresponded to our earlier finding of decreased intestinal transepithelial electrical resistance (TEER) after CBDL (Alaish et al. [@b2]). In addition, this time point exhibited differences in TEER based on the genetic background of the mouse (Alaish et al. [@b2]). These TEER findings were found in both the jejunum and ileum and correlated with differences in bacterial translocation and mortality. Further studies on jejunal tissue demonstrated differences in tight junction protein expression between CBDL and sham animals and between the strains (Alaish et al. [@b2]). Therefore, in this study, we chose jejunum once again; the intestinal tissue was harvested under sterile conditions. RNA extraction and purification were performed as we have previously described (Dorsey et al. [@b16]).

### Microarray data analysis

Microarray expression profiling was performed according to the manufacturer protocols (Affymetrix, Santa Clara, CA). Briefly, total RNA was used to prepare biotinylated cRNA, followed by fragmentation and hybridization to Affymetrix arrays (Genechip Mouse 430 2.0; Affymetrix, Santa Clara, CA). The arrays were incubated for approximately 16 h, washed, stained, and scanned per Affymetrix. Differential gene expression through microarray was then performed. We utilized.cel files generated from Affymetrix profiling process for analysis. Arrays were normalized by GCRMA method implemented in gcrma R package (Bioconductor, an open source collection of software packages). Differential expression analysis was performed using limma R package (Bioconductor). First, a linear model was fitted to expression data for each gene. Empirical Bayes method was then used to assess differential expression between two conditions. A cutoff of FDR less than 0.05 was used to select significant probes. A complete data set has been submitted to the NCBI Gene Expression Omnibus (NCBI GEO \#GSE47099 and NCBI Tracking System \#16793295).

### qPCR verification of promising candidate genes

The identification of significant changes in expression of promising candidate genes (major urinary proteins \[MUPs\], serine protease-1-inhibitor \[Serpina1a\] and lipocalin-2 \[LCN2\]) through microarray analysis was validated using a quantitative polymerase chain reaction (qPCR) technique. Total RNA was isolated from homogenized jejunal samples that were stored in TRIzol (Invitrogen, Grand Island, NY). The total RNA was isolated from TRIzol samples as per the manufacturer\'s instructions. The pellet was allowed to air dry, and the total RNA was resuspended in an appropriate volume of RNAse-free water. RNA concentrations were calculated using a NanoDrop 1000 spectrophotometer (Thermo Scientific, Waltham, MA). Single-stranded cDNA was synthesized from 2 μg of total RNA using random hexamer primer and the First-Strand cDNA Synthesis Kit (MBI Fermentas, Hanover, MD). The specific primer sequences were designed using Beacon Designer 7.0 (Premier Biosoft International, Palo Alto, CA) and synthesized by the University of Maryland School of Medicine Biopolymer/Genomics Core. qPCR reactions were set up using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA) in a total volume of 25 μL. Amplification conditions were as follows: 95°C for 3 min, 50 cycles of 95°C for 15 sec, 60°C for 15 sec, and 72°C for 20 sec. All reactions were performed using Bio-Rad iCycler instrumentation and software. All samples were normalized with 18s rRNA housekeeping gene levels with subsequent calculation of fold change in mRNA expression. Analysis was carried out in GraphPad Prism5 (San Diego, CA, USA).

### Mortality following CBDL in matriptase hypomorphic B6 mice

We conducted a mortality study following CBDL in wild-type C57BL/6J mice (*n* = 8) and matriptase (*St14*) hypomorphic C57BL/6J mice (*n* = 11). Sham-operated mice of each strain served as controls.

### Cells

Cdx2-intestinal epitheial cells (Cdx2-IEC), a transformed rat crypt IEC-6 cell line which maintains a stable differentiated phenotype upon future passages, were obtained from Dr. J.-Y. Wang (University of Maryland, Baltimore, MD). Cdx2-IEC cells were maintained at 37°C in a humidified incubator with 10% CO~2~ in DMEM containing 5% (v:v) fetal bovine serum (FBS), 0.5% (v:v) ITS + liquid media supplement, 0.1 million units/L penicillin, 100 mg/L streptomycin, and 4 mmol/L sopropylthio-β-[d]{.smallcaps}-galactoside, which served as an inducer.

### Transfection of Cdx2-IEC cells with MUP-1 siRNA and FITC-dextran permeability assay

Following their sixth passage, Cdx2-IEC cells were transfected with either MUP-1 siRNA (Thermo Scientific, Inc.) or Acell Control Non-Targeting siRNA (Thermo Scientific, Inc.) as described previously (Rao et al. [@b33]). The siRNAs used were as follows: 80 nmol/L Control siRNA; and 20 nmol/L, 40 nmol/L, and 60 nmol/L MUP-1 siRNA. Silencing of MUP-1 in the cells was confirmed by Western blot analysis using MUP (F-3) mouse monoclonal antibody (Santa Cruz Biotechnology, Inc., Paso Robles, CA, USA). Six-well transwell plates with 12-mm-diameter inserts (Costar 3407; Corning, Inc., Kennebunk, ME, USA) were used to perform the permeability studies following the transfection. The cells were incubated on the inserts with control media for 24 h to allow proper attachment to the membrane prior to dextran administration. After 24 h, TEER was measured in both control and transfected Cdx2-IEC cells for the formation of the monolayer as described previously (El Asmar et al. [@b17]). The media were removed. 4-kDa FITC-dextran in control media was placed onto the apical side (top chamber); control media alone was placed on the basolateral side. The TEER was monitored for 2 h and 100-μL aliquots of the basolateral medium were collected after each 30-min time period. A sample from the top compartment at the time of the last sampling of the bottom compartment was used to normalize the samples to account for possible differences in the total fluorescence added at the beginning of the experiment. Fluorescence of the samples was quantified in a multiplate fluorescence reader in black 96-well plates; the excitation wavelength was 485 nm and emission wavelength was 538 nm.

Statistical analysis
--------------------

The microarray data (reported as percent change) were analyzed using repeated measures analyses of variance (ANOVA) with false discovery rate correction to control multiple testing errors. Post hoc testing was done using Tukey\'s honestly significant difference (HSD). qPCR data were analyzed using ANOVA with the Bonferroni posttest. Graph Pad Prism 5 software was used. For the matriptase hypomorphic B6 mouse CBDL experiment, a Kaplan--Meier survival curve was generated with *P* \< 0.05 considered as significant.

Results
=======

Microarray data
---------------

As shown in Figure [1](#fig01){ref-type="fig"}A, more than 500 genes were significantly differentially regulated in the CBDL mice compared with sham. When examining changes across strains, although there are shared genes, there are a significant number of differentially regulated genes that are unique to each strain (Fig. [1](#fig01){ref-type="fig"}B). Table [1](#tbl1){ref-type="table"} shows the number of genes in each category**.** The first two lines of data in Table [1](#tbl1){ref-type="table"} demonstrate that many more genes are differentially expressed in A/J mice as compared to B6 mice following CBDL (582 vs. 137). The last two lines of data in Table [1](#tbl1){ref-type="table"} demonstrate that there are more genes undergoing expression changes following CBDL compared to sham (882 vs. 766). In Figure [1](#fig01){ref-type="fig"}C, the heat map shows clustering of all differentially expressed genes by genotype. A list of all differentially expressed genes can be found in [Table A1](#tbl2){ref-type="table"}. In Figure [1](#fig01){ref-type="fig"}D, the top 53 significantly regulated genes across the two strains are shown in a separate heat map (For both heat maps, red = upregulated genes; green = downregulated genes). Note the disparate gene expressions in the two strains.

###### 

Differentially expressed genes with FDR \< 0.05

                         Total   Up    Down
  ---------------------- ------- ----- ------
  A/J CBDL versus sham   582     404   178
  B6 CBDL versus sham    137     76    61
  Sham A/J versus B6     766     276   490
  CBDL A/J versus B6     882     291   591

![Venn diagram and heat map depicting the number of statistically significant differentially expressed genes by experimental condition and across murine strains. The venn diagram in (A) depicts the number of genes that are differentially expressed in the surgical group versus sham. In (B) we show the number of differentially expressed genes across two strains, A/J and B6. (C) The heat map shows all differentially expressed genes between strains. (D) A heat map which shows the top 53 significantly regulated genes across two strains. For both heat maps, red = upregulated genes; green = downregulated genes.](phy20001-e00073-f1){#fig01}

We next examined significantly enriched canonical signaling pathways. First, we evaluated those that were unique within a strain in the CBDL condition compared with sham. As shown in Figure [2](#fig02){ref-type="fig"}A, coagulation pathways were highly upregulated in A/J CBDL mice compared with sham. In contrast, coagulation pathways were not significantly regulated in B6 CBDL versus sham (Fig. [2](#fig02){ref-type="fig"}B). In Figure [2](#fig02){ref-type="fig"}C, we show that there are a number of signaling pathways that are differentially regulated in A/J CBDL compared with B6 CBDL, demonstrating differential pathway activation in CBDL across these two inbred strains of mice.

![Significantly enriched canonical signaling pathways from differentially expressed gene sets. As denoted by the blue arrows in (A), coagulation pathways were highly upregulated in CBDL AJ mice compared with sham. In contrast, coagulation pathways were not significantly regulated in B6 CBDL versus sham (B). In (C), we show that there are a number of signaling pathways that are differentially regulated in AJ CBDL compared with B6 CBDL, demonstrating differential pathway activation in CBDL across these two inbred strains of mice.](phy20001-e00073-f2){#fig02}

qPCR verifies microarray results of candidate genes
---------------------------------------------------

The following genes struck us as particularly promising as candidate genes to limit cholestatic injury: MUPs, Serpina1a, and LCN2. They all had significant changes in gene expression following CBDL. MUPs and Serpina1a also had disparate strain expressions which could account for the phenotypic differences we see following ligation. LCN2 was chosen because it is known to play a protective role in the intestinal barrier (Berger et al. [@b5]). Although we did not see strain differences in LCN2, we did find striking differences between the sham and CBDL mice, which we believe is an important finding. This study not only illustrates strain differences following CBDL but also serves to illustrate intestinal gene expression changes following CBDL independent of strain. qPCR did, indeed, verify our results for MUPs, Serpina1a, and LCN2. (Fig. [3](#fig03){ref-type="fig"}A--C).

![Serpina 1a, MUPs, and LCN2 gene expression changes determined by qPCR are consistent with microarray findings. (A) demonstrates a marked increase in Serpina 1a mRNA following CBDL in both strains. Also, there is a strain difference with increased Serpina 1a mRNA expression in B6 as compared to A/J mice. (B) demonstrates marked strain differences in MUP mRNA expression in the sham animals with disparate responses to CBDL. A/J sham MUP mRNA expression is low and expression increases following CBDL; whereas, in the B6 strain, MUP mRNA expression is very high in the sham group but falls in the CBDL group. (C) shows low expression of LCN2 mRNA in sham animals with marked increases following CBDL in both strains.](phy20001-e00073-f3){#fig03}

Matriptase (St14) hypomorphic B6 mice do not have significantly increased mortality following CBDL compared to wild-type B6 mice
--------------------------------------------------------------------------------------------------------------------------------

Serpina1a is a serine protease inhibitor, suggesting that decreased intestinal serine protease activity could contribute to the decreased intestinal resistance associated with CBDL. Matriptase is a serine protease whose loss results in decreased intestinal resistance as measured by decreased intestinal TEER (Buzza et al. [@b7]). We hypothesized that when coupled with the loss of matriptase, the increase in Serpina1a which follows CBDL would result in such a large drop in intestinal resistance that mortality would increase. Although there appeared to be a trend toward increased mortality in the matriptase (*St14*) hypomorphic B6 mice early on following CBDL, this difference never became significant and did not persist, as can be seen in the Kaplan--Meier Survival Curve (Fig. [4](#fig04){ref-type="fig"}).

![Kaplan--Meier survival curve for matriptase hypomorphic B6 and wild-type B6 mice following CBDL. The early trend toward increased mortality in the matriptase hypomorphic B6 mice is not statistically significant.](phy20001-e00073-f4){#fig04}

MUP-1 siRNA transfection increases permeability in Cdx2-IEC cells
-----------------------------------------------------------------

Growth hormone treatment has beneficial effects on the intestine by normalizing intestinal permeability (Liu et al. [@b28]). We hypothesize that increased expression of MUPs by growth hormone activation (Kuhn et al. [@b26]) could contribute to this beneficial effect. We inhibited MUP-1 protein expression using siRNA technology. Following confirmation of inhibition of MUP-1 protein expression (Fig. [5](#fig05){ref-type="fig"}), we performed a FITC-dextran permeability assay on Cdx2-IEC cells alone, Cdx2-IEC cells exposed to calcium-free media, Cdx2-IEC cells exposed to control siRNA, and Cdx2-IEC cells exposed to two different concentrations of MUP-1 siRNA (Fig. [6](#fig06){ref-type="fig"}). As expected, cells exposed to calcium-free media resulted in a marked increase in cell permeability compared to Cdx2-IEC cells in control media (\**P* \< 0.04). Cells treated with Control siRNA at 80 nmol/L and MUP-1 siRNA at 40 nmol/L concentrations were similar to untreated cells; whereas, cells treated with MUP-1 siRNA at 60 nmol/L concentration had significantly increased cell permeability compared to Cdx2-IEC cells in control media (\*\**P* \< 0.0002). Indeed, permeability of cells treated with MUP-1 siRNA at 60 nmol/L concentration was similar to cells in calcium-free media.

![Western blot demonstrating silencing of MUP-1. Following their sixth passage, Cdx2-IEC cells were transfected with either MUP-1 siRNA (Thermo Scientific, Inc.) or Acell Control Non-Targeting siRNA (Thermo Scientific, Inc.). Western blot analysis was performed using MUP (F-3) mouse monoclonal antibody (Santa Cruz Biotechnology, Inc.).](phy20001-e00073-f5){#fig05}

![FITC-dextran permeability assay in Cdx2-IEC cells. Cells exposed to calcium-free (Ca-free) media resulted in a marked increase in cell permeability compared to Cdx2-IEC cells in control media (\**P* \< 0.04). Cells treated with Control siRNA at 80 nmol/L and MUP-1 siRNA at 40 nmol/L concentrations were similar to untreated cells; whereas, cells treated with MUP-1 siRNA at 60 nmol/L concentration had significantly increased cell permeability compared to Cdx2-IEC cells in control media (\*\**P* \< 0.0002). Indeed, permeability of cells treated with MUP-1 siRNA at 60 nmol/L concentration was similar to cells in calcium-free media.](phy20001-e00073-f6){#fig06}

Discussion
==========

Cholestasis can arise from a multitude of conditions in both the adult and pediatric population. In broad terms, cholestasis may result from biliary tract obstruction or hepatic parenchymal disease. Causes of biliary tract obstruction in the adult include pancreatic carcinoma, duodenal carcinoma and cholangiocarcinoma, benign biliary strictures, and choledochal cyst; whereas, biliary atresia and choledochal cyst are seen in infants and children. Causes of hepatic parenchymal disease in both age groups include hepatitis, total parenteral nutrition, sepsis, and other more rare cholestatic syndromes. In the neonatal population, cholestasis is commonly associated with a variety of intestinal pathologies, including necrotizing enterocolitis, intestinal atresias, midgut volvulus, gastroschisis, and Hirschsprung disease. In these conditions, a baby may not be able to tolerate much or any nutrition enterally. Total parenteral (intravenous) nutrition is required. As mentioned earlier, this type of nutrition causes cholestasis and the lack of enteral nutrition worsens the cholestasis; whereas, initiation of enteral nutrition and discontinuation of parenteral nutrition result in improvement of cholestatic liver dysfunction (Javid et al. [@b22]).

The goal of this study was to use microarray technology to generate candidate genes from both existing and novel pathways which play a role in the development of intestinal injury following cholestasis as modeled by CBDL. Using two different inbred strains of mice, A/J and C57Bl/6J, the design of this study had the benefit of not only discovering strain-independent but also strain-dependent changes in intestinal gene expression following cholestasis. More than 500 genes were increased by more than 2.0-fold following CBDL, and the following were identified as promising candidate genes for further study: MUPs, Serpina1a, and LCN-2.

Major urinary proteins (MUPs) comprise the lipocalin superfamily of lipophilic ligand carriers which, until recently, were thought to participate exclusively in pheromone function. In a seminal article from 2009, MUP1 was shown to be a regulator for glucose and lipid metabolism, in addition to its action as a pheromone ligand to mediate chemical signaling in mice (Zhou et al. [@b42]). MUP production is known to be increased by testosterone, thyroid hormone, and growth hormone (GH) (Kuhn et al. [@b26]). The latter hormone is well known to play a significant role in intestinal healing following injury. Increased growth of the small bowel mucosa has been demonstrated in mice overexpressing bovine growth hormone (Ulshen et al. [@b35]). Moreover, recombinant growth hormone significantly attenuated intestinal mucosal injuries and bacterial translocation in septic rats (Yi et al. [@b40]), possibly through a mechanism involving the rhGH inhibition of apoptosis of intestinal mucosa cells. Endotoxemia was also reduced after GH administration in jaundiced rats (Scopa et al. [@b34]). Some insight into the mechanism(s) by which GH exerts it effects have been elucidated in animal models. Prophylactic treatment with growth hormone promoted IgA secretion by B lymphocytes in the plasma and in the intestine in stressed postoperative rats (Ding et al. [@b15]). Similar effects have been seen in patients. GH was found to attenuate the depression in cellular immunity following surgical stress in a randomized, double-blind, controlled trial of 20 patients undergoing abdominal surgery (Liu et al. [@b28]). In addition, GH contributes to intestinal adaptation and has been documented to enable both adult and pediatric short gut syndrome patients to graduate from total parenteral nutrition (TPN) supplementation (Byrne et al. [@b8]; Velasco et al. [@b36]; Weiming et al. [@b37]). Growth hormone was also shown to reduce the increase in intestinal permeability seen following abdominal surgery (Liu et al. [@b28]). Consequently, when our microarray analysis demonstrated MUPs 1, 2, 3, 4, 7, 11, and 20 to be significantly increased following CBDL, we sought to explore this possible mechanism further. qPCR validated the microarray results and demonstrated a \>200-fold increase in MUP expression in B6 sham mice compared to A/J sham mice. Most interestingly, the two strains of mice had different responses to CBDL. MUP expression increased \>5-fold in A/J mice following CBDL; however, MUP expression in B6 mice decreased greatly following CBDL, such that there was no significant difference between two strains following CBDL**.** We speculate that GH rises in A/J mice following CBDL to increase MUP expression which, in turn, leads to increased intestinal resistance, strengthens the intestinal barrier, and helps limit injury; whereas, in B6 mice, GH reserves and MUP expression have been depleted and simply cannot keep up with the injury. Further work is needed to clarify this.

We documented baseline expression of MUP-1 in intestinal epithelial cells. Following transfection of these cells with MUP-1 siRNA at 60 nmol/L concentration, we noticed a marked increase in cell permeability. This finding implicates increased MUP expression leading to increased intestinal resistance as a mechanism potentially responsible for the beneficial effects of growth hormone therapy.

Serpina1a is a gene on Chromosome 14 that encodes alpha-1 antitrypsin, which is a type of serine protease inhibitor, serpin. Our microarray analysis demonstrated a markedly elevated level of Serpina1a gene expression in the B6 sham mice, as well as dramatic increases in Serpina1a gene expression following CBDL in both strains. qPCR confirmed these findings. B6 sham mice had approximately 50-fold increased levels of expression compared to A/J sham mice. Furthermore, both strains exhibited approximately 100-fold increased levels of expression following CBDL when compared to the A/J sham mice.

A novel mechanism was suggested by the work of Bacher et al. ([@b3]). They found that in gastrointestinal cell lines, the formation of tight junctions involves cellular proteases which are susceptible to protease inhibitors. Moreover, the recent work by Buzza and colleagues ([@b7]) showing that Matriptase, a membrane-type serine protease-1, regulated epithelial barrier formation and permeability in the intestine intrigued us. Using matriptase (*St14*) hypomorphic mice which express less than 1% of the gene product, Buzza and colleagues ([@b7]) demonstrated these mice to have a leaky intestinal barrier with decreased TEER and increased paracellular permeability. This raised the hypothesis that matriptase (*St14*) hypomorphic mice would have a higher mortality following CBDL than wild-type B6 mice**.** The increased expression of Serpina1a, coupled with the decreased intestinal resistance that we had found following CBDL, suggested to us that matriptase (*St14*) hypomorphic mice with decreased intestinal resistance and leaky tight junctions would not tolerate CBDL and the resultant further inhibition of serine protease-1 as well as the wild-type B6 mice. To our surprise, we did not find a striking effect on mortality. This might be explained in part by the work of Beliveau et al. ([@b4]) which showed that under in vitro conditions, Serpina1a was an impotent inhibitor of matriptase compared to other serpins, such as antithrombin III. Antithrombin III may very well inhibit matriptase in vivo; however, further experiments would be necessary to confirm this. Whether antithrombin III increases mortality in matriptase hypomorphic mice following CBDL might be confounded by the known salutary effects of antithrombin III in sepsis, including the attenuation of both hepatocyte apoptosis (Huang et al. [@b21]) and endotoxemia-induced healing impairment in the colon (Diller et al. [@b14]), as well as preserved mucosal thickness and villus height following CBDL (Caglikulekci et al. [@b9]). Nevertheless, our results suggest that matriptase does not play a significant role in the mortality following CBDL.

A potential mechanism behind the role of Serpina1a in the cholestatic intestine might be akin to that seen in studies of lung inflammation. Alpha-1 antitrypsin inhibits the enzyme, neutrophil elastase, which is released from neutrophils and macrophages during inflammation; neutrophil elastase destroys both bacteria and host tissue. Neutrophil elastase has also been shown to play a significant role in the pathogenesis of lung injury in pulmonary fibrosis (Yamanouchi et al. [@b39]). Moreover, alpha-1 antitrypsin was shown to induce hepatocyte growth factor (HGF) production by human lung fibroblasts and function as an anti-inflammatory and regenerative factor in addition to its role in protease inhibition (Kikuchi et al. [@b25]). HGF has previously been shown to increase intestinal epithelial cell mass and function in vivo (Kato et al. [@b23]) and also stimulate DNA content and protein content beyond the normal adaptive response following massive small intestinal resection (Kato et al. [@b24]). Our data suggest that increased expression of Serpina1a would increase HGF and provide a therapeutic approach to limit the intestinal injury following cholestasis, analogous to a recent study, in which alpha-1 antitrypsin therapy was shown to decrease intestinal permeability and ameliorate acute colitis and chronic ileitis in a murine model (Collins et al. [@b12]).

Lipocalin-2 is an iron-sequestering protein in the antibacterial innate immune response. Upon encountering invading bacteria, the Toll-like receptor 4 (TLR4) on immune cells stimulates the transcription, translation, and secretion of lipocalin-2 (Flo et al. [@b18]). It binds to siderophores secreted by pathogenic bacteria, including enterochelin secreted by *E. coli*, and prevents bacterial iron uptake (Flo et al. [@b18]). LCN2^−/−^ mice have decreased survival following *E. coli* infection compared to wild-type mice (Berger et al. [@b5]). Neutrophils isolated from LCN2^−/−^ mice showed significantly less bacteriostatic activity compared with wild-type controls. The bacteriostatic property of the wild-type neutrophils was abolished by the addition of exogenous iron, indicating that the main function of lipocalin-2 is to limit this essential element (Berger et al. [@b5]). Similarly, lipocalin-2 resistance confers an advantage to *Salmonella enterica* serotype Typhimurium for growth and survival in the inflamed intestine (Rafatellu et al. [@b32]). Our microarray analysis demonstrated significant increases in LCN2 following CBDL. qPCR confirmed this finding and is consistent with a strain-independent response to CBDL. LCN2 expression increased more than 20-fold and 40-fold, respectively, in A/J and B6 mice following CBDL. Increased LCN2 gene expression in the intestine following CBDL appears to be a mechanism whereby the host limits injury and mortality. This appears analogous to the increase in LCN2 gene expression coincident with an increase in epithelial cell apoptosis associated with intestinal adaptation following massive small bowel resection (Wildhaber et al. [@b38]). This is in agreement with earlier work by Devireddy et al. ([@b13]) demonstrating lipocalin-2 to induce apoptosis in hematopoietic cells by an autocrine pathway. Thus, lipocalin-2 is a regulatory factor of intestinal growth.

In summary, our study has generated a resource of candidate genes for intestinal injury secondary to cholestasis. For Serpina1a, MUPs, and LCN2, some of the genes whose expression was most dramatically affected by CBDL, we confirmed the microarray results with qPCR. Novel mechanisms implicated by our results involve the growth hormone pathway, the acute phase response, and the innate immune response. More research is needed to further define these mechanisms; however, future therapeutic strategies might include: overexpression of Serpina1a and increased levels of HGF, upregulation of the GH pathway and increased MUP expression, and increased LCN2 expression to limit intestinal injury following cholestasis.
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Table A1List of all differentially expressed genesProbe set IDGene accessionGene symbolGene descriptionCytobandAJ CBDL vs sham FCAJ CBDL vs sham FDRB6 CBDL vs sham FCB6 CBDL vs sham FDR10566477NM_017371**Hpx**hemopexin7 F1**37.40121.00E−044.74080.0435**10581605NM_017370**Hp**haptoglobin8 D3\|8 55.0 cM**34.1523.00E−046.6620.0445**10505438NM_008768**Orm1**orosomucoid 14 B3\|4 31.4 cM**18.20622.00E−044.38260.0404**10414192NM_133653**Mat1a**methionine adenosyltransferase I, alpha14 C1**17.9810.0017.2680.0306**10511886NM_016668 // NM_016668**Bhmt // Bhmt**betaine-homocysteine methyltransferase // betaine-homocysteine methyltransferase13 D1 // 13 D1**17.94850.001410.42110.0197**10457114NM_016668**Bhmt**betaine-homocysteine methyltransferase13 D1**15.65495.00E−048.39980.0109**10578352NM_145594**Fgl1**fibrinogen-like protein 18 A4**13.88911.00E−044.11480.0178**10575349NM_146214**Tat**tyrosine aminotransferase8 D3**12.47523.00E−044.3230.0294**10449452NM_010220**Fkbp5**FK506 binding protein 517 A3.3\|17 13.0 cM**11.85210.00156.3590.0294**10490989NM_001042611**Cp**ceruloplasmin3 D**11.116203.38520.0109**10481627NM_008491**Lcn2**lipocalin 22 A3\|2 27.0 cM**9.71868.00E−048.09140.0098**10360328NM_011318**Apcs**serum amyloid P-component1 H3\|1 94.2 cM**9.216603.12530.0123**10451953NM_029796**Lrg1**leucine-rich alpha-2-glycoprotein 117 D\|17 10.0 cM**6.99196.00E−045.00510.0109**10574023NM_008630**Mt2**metallothionein 28 C5\|8 45.0 cM**6.96970.02068.45490.0307**10515187NM_007822**Cyp4a14**cytochrome P450, family 4, subfamily a, polypeptide 144 D1\|4 49.5 cM**4.66090.03789.82820.015**10418434NM_008407**Itih3**inter-alpha trypsin inhibitor, heavy chain 314 A2-C1**4.20719.00E−044.05940.0078**10543017NM_013743**Pdk4**pyruvate dehydrogenase kinase, isoenzyme 46 A1\|6 0.63 cM**3.51930.01453.4920.0368**10503520NM_015767**Ttpa**tocopherol (alpha) transfer protein4 A3\|4 22.7 cM**3.33380.0032.57560.0354**10492748NM_010196**Fga**fibrinogen alpha chain3 F1\|3 44.8 cM**3.10770.00132.25120.0307**10496727NM_026993**Ddah1**dimethylarginine dimethylaminohydrolase 13 H3**3.06940.0012.9670.0098**10583732NM_010700**Ldlr**low density lipoprotein receptor9 A3\|9 5.0 cM**3.052702.07550.0024**10507177NM_001100181**Cyp4a32**cytochrome P450, family 4, subfamily a, polypeptide 324 D1**2.78530.03473.39320.0344**10527920NM_020010**Cyp51**cytochrome P450, family 515 A2\|5 1.2 cM**2.77080.0012.30880.015**10362073NM_001161845**Sgk1**serum/glucocorticoid regulated kinase 110 A3**2.74120.00733.46890.0109**10379153NM_009657**Aldoc**aldolase C, fructose-bisphosphate11 B5\|11 44.98 cM**2.6990.00962.62460.0301**10420730NM_010191**Fdft1**farnesyl diphosphate farnesyl transferase 114 D1\|14 3.0 cM**2.61510.0012.02280.0228**10515201NM_007823**Cyp4b1**cytochrome P450, family 4, subfamily b, polypeptide 14 D1\|4 49.5 cM**2.56140.0011.78620.0445**10568001NM_133670**Sult1a1**sulfotransferase family 1A, phenol-preferring, member 17 F3\|7 4.0 cM**2.51991.00E−041.78990.0109**10520362NM_153526**Insig1**insulin induced gene 15 B1**2.46310.00141.8360.0451**10412909NM_010191**Fdft1**farnesyl diphosphate farnesyl transferase 114 D1\|14 3.0 cM**2.43066.00E−042.0720.0109**10424349NM_009270**Sqle**squalene epoxidase15 D1**2.36830.00231.96090.0307**10478048NM_008489**Lbp**lipopolysaccharide binding protein2 H1\|2 83.0 cM**2.34046.00E−041.81610.0194**10499483NM_134469**Fdps**farnesyl diphosphate synthetase3 F1\|3 42.6 cM**2.23160.00442.21710.017**10412466NM_145942**Hmgcs1**3-hydroxy-3-methylglutaryl -Coenzyme A synthase 1---**2.2130.00121.77490.0294**10364194NM_146006**Lss**lanosterol synthase10 C1\|10 41.1 cM**2.12560.00511.90210.0346**10378793NM_025655**Tmigd1**transmembrane and immunoglobulin domain containing 111 B5**2.06430.03163.02210.0109**10365830---**---**------**2.05330.00321.95760.0178**10542470NM_019946**Mgst1**microsomal glutathione S-transferase 16 G1**1.99510.01241.92030.0416**10506571NM_053272**Dhcr24**24-dehydrocholesterol reductase4 C7**1.88360.00141.87090.0109**10450242NM_009780**C4b**complement component 4B (Childo blood group)17 B1\|17 18.8 cM**1.86070.01241.8490.0333**10585942NM_001033498**Gramd2**GRAM domain containing 29 B**1.82640.00371.6220.0375**10493548NM_026784**Pmvk**phosphomevalonate kinase3 F1**1.78520.01051.8080.0273**10492964NM_009690**Cd5l**CD5 antigen-like3 F1**1.62840.01951.85390.0169**10524555NM_023556**Mvk**mevalonate kinase5 F\|5 64.0 cM**1.60430.01441.630.0307**10600082NM_010941**Nsdhl**NAD(P) dependent steroid dehydrogenase-likeX A7.3\|X 28.87 cM**1.57270.0091.71570.0116**10573626NM_173866**Gpt2**glutamic pyruvate transaminase (alanine aminotransferase) 28 C3**1.52930.04381.66330.0425**10526630NM_015799**Trfr2**transferrin receptor 25 G2**1.51750.01971.52380.0435**10456699NM_177470**Acaa2**acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacy l-Coenzyme A thiolase)18 E2\|18 45.0 cM**1.50950.0291.65370.0273**10393970NM_007988**Fasn**fatty acid synthase11 E2\|11 72.0 cM**1.47690.0041.48460.015**10525893NM_030210**Aacs**acetoacetyl-CoA synthetase5 F**1.46730.02421.48960.0456**10425695NM_033218**Srebf2**sterol regulatory element binding factor 215 E1**1.46330.00951.48260.0233**10569972NM_026058**Lass4**LAG1 homolog, ceramide synthase 48 A1.2**1.43180.01451.50.0228**10570437NM_025785**Fbxo25**F-box protein 258 A1.1**−1.38090.0356−1.49530.0294**10447239NM_026180**Abcg8**ATP-binding cassette, sub-family G (WHITE), member 817 E4\|17 54.5 cM**−1.55840.013−1.80030.0109**10425945NM_010180**Fbln1**fibulin 115 E-F**−1.56720.013−1.6010.0287**10453318NM_031884**Abcg5**ATP-binding cassette, sub-family G (WHITE), member 517 E4\|17 54.5 cM**−1.68290.0069−1.68780.0224**10390032NM_153807**Acsf2**acyl-CoA synthetase family member 211 D**−1.88210.0041−2.2280.0078**10492426NM_153807**Acsf2**acyl-CoA synthetase family member 211 D**−1.95670.0045−2.12360.0109**10518674NM_022020**Rbp7**retinol binding protein 7, cellular4 E2**−2.07390.0021−1.81520.0258**10462442NM_001164724**Il33**interleukin 3319 C2**−2.09350.0078−1.94540.0354**10575833NM_008290**Hsd17b2**hydroxysteroid (17-beta) dehydrogenase 28 E1**−2.20550.0025−1.94590.026**10577655NM_008324**Ido1**indoleamine 2,3-dioxygenase 18 A2**−2.44590.0461−3.45930.0249**10463005NM_028089**Cyp2c55**cytochrome P450, family 2, subfamily c, polypeptide 5519 C3**−2.55590.0458−14.64164.00E−04**10373334NM_013786**Hsd17b6**hydroxysteroid (17-beta) dehydrogenase 610 D3**−2.61862.00E−04−1.71220.0241**10502214NM_027816**Cyp2u1**cytochrome P450, family 2, subfamily u, polypeptide 13 H1**−3.43071.00E−04-1.66520.0425**10514912NM_007860**Dio1**deiodinase, iodothyronine, type I4 C7\|4 48.7 cM**−4.50640.0012−3.89380.0109**10480155NM_001081084**Cubn**cubilin (intrinsic factor -cobalamin receptor)2 A1\|2 9.0 cM**−4.81233.00E−04−2.77930.016**10585749NM_009992**Cyp1a1**cytochrome P450, family 1, subfamily a, polypeptide 19 B\|9 31.0 cM**−5.65070.001−3.31350.0301**10513420NM_001134675**Mup7**major urinary protein 74 B3\|4**127.86180.001**10513455NM_008647**Mup2**major urinary protein 24 B3**126.97890.001**10513437NM_001164526**Mup11**major urinary protein 114 B3**117.18010.001**10513428NM_001045550**Mup2**major urinary protein 24 B3**113.57030.001**10513472NM_008647**Mup2**major urinary protein 24 B3**104.55630.001**10513504NM_001045550**Mup2**major urinary protein 24 B3**100.78760.001**10513497NM_001045550**Mup2**major urinary protein 24 B3**94.29110.001**10513521NM_001012323**Mup20**major urinary protein 204 B3**93.19780.0021**10513467NM_001045550**Mup2**major urinary protein 24 B3**90.62750.001**10513512NM_001163011**Mup1**major urinary protein 14 B3\|4 27.8 cM**73.99910.001**10523062NM_009654**Alb**albumin5 E1\|5 50.0 cM**61.25314.00E−04**10434689NM_013465**Ahsg**alpha-2-HS-glycoprotein16 B1\|16 15.0 cM**58.11973.00E−04**10531149NM_008096**Gc**group specific component5 E1\|5 44.0 cM**52.34231.00E−04**10492735NM_133862**Fgg**fibrinogen gamma chain3 E3\|3 41.3 cM**38.75261.00E−04**10498981NM_181849**Fgb**fibrinogen beta chain3 E3\|3 48.2 cM**38.23361.00E−04**10402406NM_009245**Serpina1c**serine (or cysteine) peptidase inhibitor, clade A, member 1C12 E\|12 51.0 cM**30.33893.00E−04**10402399NM_009243**Serpina1a**serine (or cysteine) peptidase inhibitor, clade A, member 1A12 E\|12 51.0 cM**23.96933.00E−04**10558673NM_021282**Cyp2e1**cytochrome P450, family 2, subfamily e, polypeptide 17 F5\|7 68.4 cM**21.93420.0012**10562169NM_032541**Hamp**hepcidin antimicrobial peptide7 B1\|7 11.0 cM**21.13490.004**10434719NM_001102411**Kng1**kininogen 116 B1**19.66567.00E−04**10402409NM_009247**Serpina1e**serine (or cysteine) peptidase inhibitor, clade A, member 1E12 E**18.91723.00E−04**10548207NM_007376**Pzp**pregnancy zone protein6 F1-G3\|6 62.0 cM**18.35153.00E−04**10402390NM_009244**Serpina1b**serine (or cysteine) preptidase inhibitor, clade A, member 1B12 E\|12 51.0 cM**15.52855.00E−04**10498921NM_019911**Tdo2**tryptophan 2,3-dioxygenase3 E3**13.92260.0023**10596148NM_133977**Trf**transferrin9 F1-F3\|9 56.0 cM**13.35684.00E−04**10382189NM_013475**Apoh**apolipoprotein H11 D\|11 63.0 cM**13.11930.001**10553274NM_011314**Saa2**serum amyloid A 27 B4\|7 23.5 cM**10.91740.015**10541480NR_027619**Mug-ps1**murinoglobulin, pseudogene 16 F1**10.25990.0013**10496825NM_009474**Uox**urate oxidase3 H2\|3 75.0 cM**10.16850.0046**10497337NM_009799**Car1**carbonic anhydrase 13 A1\|3 10.5 cM**9.99090.0175**10454192NM_013697**Ttr**transthyretin18 A2\|18 7.0 cM**9.98440.0025**10463037NM_010003**Cyp2c39**cytochrome P450, family 2, subfamily c, polypeptide 3919 C3**9.70381.00E−04**10398060NM_011458**Serpina3k**serine (or cysteine) peptidase inhibitor, clade A, member 3K12 E\|12 51.5 cM**9.54970.0042**10541448NR_027619**Mug-ps1**murinoglobulin, pseudogene 16 F1**9.43340.0027**10541410NM_008645**Mug1**murinoglobulin 16 F1**9.37640.001**10379190NM_011707**Vtn**vitronectin11 B5\|11 45.09 cM**8.99980.0014**10431915NM_027052**Slc38a4**solute carrier family 38, member 415 F1**8.99560.0027**10351546NM_013474**Apoa2**apolipoprotein A-II1 H3\|1 92.6 cM**8.80138.00E−04**10467410NM_145499**Cyp2c70**cytochrome P450, family 2, subfamily c, polypeptide 7019 C3**8.48440.0014**10467319NM_001159487**Rbp4**retinol binding protein 4, plasma19 D1\|19 38.0 cM**7.8580.0021**10542983NM_011134**Pon1**paraoxonase 16 A2\|6 0.5 cM**7.67080.021**10560618NM_007469**Apoc1**apolipoprotein C-I7 A3\|7 4.0 cM**7.66930.0065**10398075NM_009252**Serpina3n**serine (or cysteine) peptidase inhibitor, clade A, member 3N12 F1**7.43140.0115**10368343NM_007482**Arg1**arginase, liver10 A4**7.36719.00E−04**10563611NM_009117**Saa1**serum amyloid A 17 B4\|7 23.5 cM**7.17690.0095**10434709NM_053176**Hrg**histidine-rich glycoprotein16 B1\|16 14.1 cM**7.03190.0028**10513529NM_001039544**Mup3**major urinary protein 34 B3**6.98570.0286**10549154BC151094**Gm766**predicted gene 7666 G3**6.90040.0267**10413615NM_018746**Itih4**inter alpha-trypsin inhibitor, heavy chain 414 B\|14 11.75 cM**6.79510.0012**10441753NM_008877**Plg**plasminogen17 A1\|17 7.3 cM**6.2660.0022**10401289NM_001177561**Slc10a1**solute carrier family 10 (sodium/bile acid cotransporter family), member 112 D1\|12 37.0 cM**6.07850.0028**10485027NM_010168**F2**coagulation factor II2 E1\|2 47.5 cM**6.0480.0096**10402394NM_009246**Serpina1d**serine (or cysteine) peptidase inhibitor, clade A, member 1D12 E\|12 51.0 cM**6.03780.0135**10363860NM_025807**Slc16a9**solute carrier family 16 (monocarboxylic acid transporters), member 910 B5.3**5.87530.0065**10434698NM_021564**Fetub**fetuin beta16 B\|16 14.1 cM**5.74670.0098**10580635NM_053200**Ces3**carboxylesterase 38 C5**5.65660.0021**10526712NM_013478**Azgp1**alpha-2-glycoprotein 1, zinc5 G2\|5 78.0 cM**5.48240.0232**10506125NM_013913**Angptl3**angiopoietin-like 34 C6\|4 48.0 cM**5.27320.0124**10580624NM_007954**Es1**esterase 18 C5\|8 43.0 cM**5.12680.0355**10513630NM_007443**Ambp**alpha 1 microglobulin/bikunin4 C1-C3\|4 30.6 cM**5.10090.0025**10351852NM_007768**Crp**C-reactive protein, pentraxin-related1 H3\|1 94.2 cM**4.98820.0025**10363541NM_007494**Ass1**argininosuccinate synthetase 12 B\|2 20.0 cM**4.95340.0057**10480003NM_010582**Itih2**inter-alpha trypsin inhibitor, heavy chain 22 A1\|2 1.0 cM**4.95130.0059**10542615NM_020495**Slco1b2**solute carrier organic anion transporter family, member 1b26 G1\|6 67.0 cM**4.890.0212**10367221NM_133997**Apof**apolipoprotein F10 D3\|10 73.0 cM**4.87850.0025**10551287NM_133657**Cyp2a12**cytochrome P450, family 2, subfamily a, polypeptide 127 A3**4.80460.0096**10494643NM_008256**Hmgcs2**3-hydroxy-3-methylglutaryl -Coenzyme A synthase 23 F2.2\|3 48.0 cM**4.58150.0144**10563602NM_011316**Saa4**serum amyloid A 47 B4\|7 23.5 cM**4.52450.001**10471154NM_007494**Ass1**argininosuccinate synthetase 12 B\|2 20.0 cM**4.49790.0069**10357516NM_007576**C4bp**complement component 4 binding protein1 E4\|1 67.6 cM**4.42170.001**10416451NM_019775**Cpb2**carboxypeptidase B2 (plasma)14 D2**4.35460.0036**10551293NM_007817**Cyp2f2**cytochrome P450, family 2, subfamily f, polypeptide 27 A3**4.27940.0394**10398069NM_009253**Serpina3m**serine (or cysteine) peptidase inhibitor, clade A, member 3M12 E**4.27750.0231**10438681NM_201375**Kng2**kininogen 216 B1**4.24640.0051**10367215NM_133996**Apon**apolipoprotein N10 D3\|10 76.0 cM**4.22770.0021**10351015NM_080844**Serpinc1**serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 11 H2.1\|1 84.6 cM**4.19850.0034**10403322NM_030611**Akr1c6**aldo-keto reductase family 1, member C613 A2\|13 8.0 cM**4.14930.0498**10452316NM_009778**C3**complement component 317 E1-E3\|17 34.3 cM**4.11510.0339**10596718NM_023805**Slc38a3**solute carrier family 38, member 39 F1\|9 63.0 cM**4.10240.0239**10501555NM_007446**Amy1**amylase 1, salivary3 F3\|3 50.0 cM**4.10210.0069**10519497NM_054098**Steap4**STEAP family member 45 A1**3.99170.0063**10496001NM_007686**Cfi**complement component factor i3 G3\|3 66.6 cM**3.96980.0014**10475532NM_021507**Sqrdl**sulfide quinone reductase-like (yeast)2 F2**3.95950**10593225NM_001033324**Zbtb16**zinc finger and BTB domain containing 169 A5.3\|9 23.0 cM**3.89090.018**10458828NM_033037**Cdo1**cysteine dioxygenase 1, cytosolic18 C\|18 23.0 cM**3.74520.0025**10514763NM_146148**C8a**complement component 8, alpha polypeptide4 C6**3.73750.0096**10358339NM_009888**Cfh**complement component factor h1 F\|1 74.1 cM**3.68680.0032**10514532NM_010007**Cyp2j5**cytochrome P450, family 2, subfamily j, polypeptide 54 C5\|4 46.5 cM**3.66450.0256**10450038NM_020581**Angptl4**angiopoietin-like 417 B1**3.58510.0062**10511375NM_007824**Cyp7a1**cytochrome P450, family 7, subfamily a, polypeptide 14 A1**3.57970.0076**10423002NM_207216**Ugt3a1**UDP glycosyltransferases 3 family, polypeptide A115 A1**3.54540.0345**10483410NM_021022**Abcb11**ATP-binding cassette, sub-family B (MDR/TAP), member 112 C2\|2 38.4 cM**3.43060.0445**10447885NM_153151**Acat3**acetyl-Coenzyme A acetyltransferase 317 A1\|17 7.55 cM**3.36950.0023**10537169NM_009731**Akr1b7**aldo-keto reductase family 1, member B76 B1\|6 14.0 cM**3.36850.0032**10395273BC052902**Gdap10**ganglioside-induced differentiation-associated-protein 1012 A3**3.35610.0043**10503502NM_015767**Ttpa**tocopherol (alpha) transfer protein4 A3\|4 22.7 cM**3.21690.0089**10585015NM_080434**Apoa5**apolipoprotein A-V9 B**3.21530.0026**10581388NM_008490**Lcat**lecithin cholesterol acyltransferase8 D3\|8 53.0 cM**3.21030.0014**10482004BC094504**AI182371**expressed sequence AI1823712 B**3.18370.0281**10574027NM_013602**Mt1**metallothionein 18 C5\|8 45.0 cM**3.16540.0374**10379736NM_183249**1100001G20Rik**RIKEN cDNA 1100001G20 gene11 C**3.10490.0151**10420899NM_178747**Gulo**gulonolactone (L-) oxidase14 D1**3.01860.0345**10435626NM_013547**Hgd**homogentisate 1, 2-dioxygenase16 B3\|16 27.3 cM**2.96560.0296**10345065NM_001077353**Gsta3**glutathione S-transferase, alpha 31 A4\|1 15.0 cM**2.93090.0145**10356145NM_030556**Slc19a3**solute carrier family 19 (sodium/hydrogen exchanger), member 31 C5\|1 51.0 cM**2.91230.0301**10533612NM_008277**Hpd**4-hydroxyphenylpyruvic acid dioxygenase5 F\|5 67.0 cM**2.86020.0373**10451451NM_010321**Gnmt**glycine N-methyltransferase17 C\|17 10.0 cM**2.83190.0461**10543333NM_013930**Aass**aminoadipate-semialdehyde synthase6 A3.1\|6 4.5 cM**2.80690.0115**10596166NM_027918**1300017J02Rik**RIKEN cDNA 1300017J02 gene9 F1**2.77560.0308**10406646NM_028772**Dmgdh**dimethylglycine dehydrogenase precursor13 C3**2.73360.0244**10500547NM_153193**Hsd3b2**hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 23 F2.2\|3 49.1 cM**2.63990.0032**10570717NM_001177522**Gm14850**predicted gene 148508 A2**2.59730.0148**10361234NM_008288**Hsd11b1**hydroxysteroid 11-beta dehydrogenase 11 H6**2.59570.0096**10507171NM_201640**Cyp4a31**cytochrome P450, family 4, subfamily a, polypeptide 314 D1**2.5750.0484**10570732NM_001177528**Gm15315**predicted gene 153158 A2\|8**2.55920.0098**10599826NM_007979**F9**coagulation factor IXX A6-A7\|X 22.0 cM**2.54740.0143**10578916NM_025436**Sc4mol**sterol-C4-methyl oxidase-like8 B3.1**2.53790.0023**10399365NM_177802**Slc7a15**solute carrier family 7 (cationic amino acid transporter, y+ system), member 1512 A1.1**2.53570.0361**10570693NM_007851**Defa5**defensin, alpha, 58 A2**2.51810.0129**10497590NM_007963**Mecom**MDS1 and EVI1 complex locus3 A3\|3 14.4 cM**2.50470.0091**10545881NM_053096**Cml2**camello-like 26 C3**2.50130.027**10478523---**---**------**2.49620.0021**10454944NM_201256**Eif4ebp3**eukaryotic translation initiation factor 4E binding protein 318 B2**2.49510.0117**10386683NM_026183**Slc47a1**solute carrier family 47, member 111 B2**2.45340.0067**10365559NM_010512**Igf1**insulin-like growth factor 110 C1\|10 48.0 cM**2.43750.0041**10500555NM_001161742**Hsd3b3**hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 33 F2.2\|3 49.1 cM**2.41770.0094**10513412NM_008648**Mup4**major urinary protein 44 B3\|4 27.8 cM**2.39865.00E−04**10491846---**---**------**2.39360.0128**10537306NM_145364**Akr1d1**aldo-keto reductase family 1, member D16 B1**2.39240.0045**10589099NM_029634**Ip6k2**inositol hexaphosphate kinase 29 F2**2.37760.0021**10594825NM_022026**Aqp9**aquaporin 99 D**2.37230.0412**10519578NM_008830**Abcb4**ATP-binding cassette, sub-family B (MDR/TAP), member 45 A1\|5 1.0 cM**2.36720.0297**10590957NM_010242**Fut4**fucosyltransferase 49 A2\|9 3.0 cM**2.36110.0019**10447317NM_010137**Epas1**endothelial PAS domain protein 117 E4**2.29980.0142**10352000NM_133809**Kmo**kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)1 H4**2.29660.0301**10360840NM_001081361**Mosc1**MOCO sulphurase C-terminal domain containing 1---**2.26070.0105**10570660NM_001177481**Gm10104**predicted gene 101048 A2\|8**2.23770.0163**10386460NM_008819**Pemt**phosphatidylethanolamine N-methyltransferase11 B1.3\|11 31.0 cM**2.22740.0265**10576901NM_011388**Slc10a2**solute carrier family 10, member 28 A1.1\|8 2.0 cM**2.22120.0253**10530319NM_001038999**Atp8a1**ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 15 C3.1**2.18270.0152**10502050NM_027808**Alpk1**alpha-kinase 13 H1**2.16040.04**10381096NM_010517**Igfbp4**insulin-like growth factor binding protein 411 D**2.14520.0025**10408689NM_153529**Nrn1**neuritin 113 A3.3**2.11250.0301**10587266NM_010295**Gclc**glutamate-cysteine ligase, catalytic subunit9 D-E\|9 42.0 cM**2.10670.0473**10429588NM_001039720**9030619P08Rik**RIKEN cDNA 9030619P08 gene15 D3**2.10090.0025**10537146NM_008012**Akr1b8**aldo-keto reductase family 1, member B86 B1\|6 13.0 cM**2.09260.0397**10576774NM_029465**Clec4g**C-type lectin domain family 4, member g8 A1.1**2.08880.0367**10542592NR_033555**Gm10400**predicted gene 10400---**2.07290.0104**10496605NM_173763**Ccbl2**cysteine conjugate-beta lyase 23 H1**2.06850.0222**10358299NM_001029977**EG214403**predicted gene, EG2144031 F**2.06070.0386**10494023NM_011281**Rorc**RAR-related orphan receptor gamma3 F2**2.05010.0013**10357363NM_001081756**Nckap5**NCK-associated protein 51 E3**2.01910.023**10506452AY512949**AY512949**cDNA sequence AY512949---**2.01610.0416**10512895NM_007519**Baat**bile acid-Coenzyme A: amino acid N-acyltransferase4 B1\|4 22.7 cM**2.00890.0204**10388430NM_011340**Serpinf1**serine (or cysteine) peptidase inhibitor, clade F, member 111 B5**2.00360.0181**10454198NM_026301**Rnf125**ring finger protein 12518 A2**2.0030.0053**10606989NM_001077364**Tsc22d3**TSC22 domain family, member 3X F1**1.99090.0197**10418455NM_008406**Itih1**inter-alpha trypsin inhibitor, heavy chain 114 A2-C1**1.98480.0374**10365482NM_011595**Timp3**tissue inhibitor of metalloproteinase 310 C1-D1\|10 47.0 cM**1.96920.0355**10388440NM_008878**Serpinf2**serine (or cysteine) peptidase inhibitor, clade F, member 211 B5**1.96460.043**10372682NM_029875**Slc35e3**solute carrier family 35, member E310 D2**1.96410.0062**10571657NM_007981**Acsl1**acyl-CoA synthetase long-chain family member 18 B2**1.95890.0041**10581650NM_011998**Chst4**carbohydrate (chondroitin 6/keratan) sulfotransferase 4---**1.94690.039**10394990NM_026037**Mboat2**membrane bound O-acyltransferase domain containing 212 A1.3**1.94010.0244**10596072NM_001161362**Ppp2r3a**protein phosphatase 2, regulatory subunit B\'\', alpha9 E4**1.93180.0021**10411332NM_008255**Hmgcr**3-hydroxy-3-methylglutaryl-Coenzyme A reductase13 D1\|13 49.0 cM**1.92920.0013**10571840NM_008278**Hpgd**hydroxyprostaglandin dehydrogenase 15 (NAD)8 B3.2**1.92350.0025**10435787---**---**------**1.92340.0109**10555438NM_199012**Fchsd2**FCH and double SH3 domains 27 E3**1.91470.0156**10436100NM_181596**Retnlg**resistin like gamma16 B5\|16 32.5 cM**1.91260.0028**10542594AY512955**Gm10210**predicted gene 10210---**1.91070.047**10554693NM_023377**Stard5**StAR-related lipid transfer (START) domain containing 57 D3**1.9030.0204**10391744AK135410**Gpatch8**G patch domain containing 811 E1**1.90250.0148**10560624NM_009696**Apoe**apolipoprotein E7 A3\|7 4.0 cM**1.89650.0301**10542880BC048711**4833442J19Rik**RIKEN cDNA 4833442J19 gene6 G3**1.89170.0144**10461150---**---**------**1.88160.0397**10585982NM_173018**Myo9a**myosin IXa9 B**1.87640.019**10547469NM_001037155**Hsn2**hereditary sensory neuropathy, type II6 F1**1.87430.0152**10482762NM_145360**Idi1**isopentenyl-diphosphate delta isomerase13 A1**1.87220.0143**10411147NM_022884**Bhmt2**betaine-homocysteine methyltransferase 213 C3\|13 49.0 cM**1.86370.0317**10364038NM_133995**Upb1**ureidopropionase, beta10 C1**1.86070.0099**10382888AK171830**2810008D09Rik**RIKEN cDNA 2810008D09 gene---**1.85590.0272**10485170NM_009963**Cry2**cryptochrome 2 (photolyase-like)2 E**1.85530.0324**10594988NM_015806**Mapk6**mitogen-activated protein kinase 69 D\|9 38.0 cM**1.85460.0327**10535938NM_133898**N4bp2l1**NEDD4 binding protein 2-like 15 G3**1.85170.0189**10556769NM_016870**Acsm3**acyl-CoA synthetase medium-chain family member 37 F3**1.85110.0207**10401149NM_013738**Plek2**pleckstrin 212 D2**1.84290.0098**10599192NM_028894**Lonrf3**LON peptidase N-terminal domain and ring finger 3X A2**1.83740.035**10391746NM_001159492**Gpatch8**G patch domain containing 811 E1**1.83310.0248**10403413NM_145360**Idi1**isopentenyl-diphosphate delta isomerase13 A1**1.82280.0272**10580955---**---**------**1.82210.0277**10396730---**---**------**1.82180.0374**10508800AY140896**Gm3579**predicted gene 35794 D2.3\|4**1.82140.0197**10573865AY140896**Gm3579**predicted gene 35794 D2.3\|4**1.82140.0197**10558961NM_053082**Tspan4**tetraspanin 47 F5**1.81830.0132**10350753NM_008131**Glul**glutamate-ammonia ligase (glutamine synthetase)---**1.8170.0285**10351043NR_028543**Snord47**small nucleolar RNA, C/D box 471\|1**1.81560.0327**10377439NM_001159367**Per1**period homolog 1 (Drosophila)11 B**1.80920.0359**10520388NM_028234**Rbm33**RNA binding motif protein 335 B1**1.80560.0379**10370931NM_021462**Mknk2**MAP kinase-interacting serine/threonine kinase 210 C1**1.79890.0023**10582658NM_007428**Agt**angiotensinogen (serpin peptidase inhibitor, clade A, member 8)8 E2\|8 68.0 cM**1.78340.0217**10472860NM_019688**Rapgef4**Rap guanine nucleotide exchange factor (GEF) 42 C3**1.78240.0118**10505489NM_021362**Pappa**pregnancy-associated plasma protein A4 C1\|4 32.2 cM**1.78090.0012**10377751NM_009714**Asgr1**asialoglycoprotein receptor 111 B3\|11 37.0 cM**1.77930.0146**10351224NM_007976**F5**coagulation factor V1 H2.2\|1 86.6 cM**1.77350.0277**10372988NM_011391**Slc16a7**solute carrier family 16 (monocarboxylic acid transporters), member 710 D3**1.77290.0311**10351259NM_054087**Slc19a2**solute carrier family 19 (thiamine transporter), member 21 H2.2\|1 87.0 cM**1.76980.0242**10409876NM_007796**Ctla2a**cytotoxic T lymphocyte-associated protein 2 alpha13 B2\|13 36.0 cM**1.75980.0424**10410877NM_001081176**Polr3g**polymerase (RNA) III (DNA directed) polypeptide G13 C3**1.73880.0345**10424686BC025446**BC025446**cDNA sequence BC02544615 D3**1.73780.0152**10351533NM_009803**Nr1i3**nuclear receptor subfamily 1, group I, member 31 H3\|1 92.6 cM**1.72850.0341**10533050NM_030704**Hspb8**heat shock protein 85 F\|5 59.0 cM**1.7160.0394**10496872NM_133222**Eltd1**EGF, latrophilin seven transmembrane domain containing 13 H3-H4**1.71570.0233**10518743NM_173371**H6pd**hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase)4 E2\|4 78.4 cM**1.70940.0165**10487021NM_011774**Slc30a4**solute carrier family 30 (zinc transporter), member 42 E5\|2 69.0 cM**1.70660.0161**10595622---**---**------**1.70560.0342**10595636---**---**------**1.70560.0342**10595626---**---**------**1.70340.029**10446425---**---**------**1.70030.0214**10473160NM_080558**Ssfa2**sperm specific antigen 22 D**1.69080.0159**10375229---**---**------**1.69020.0112**10592938NM_138951**Ttc36**tetratricopeptide repeat domain 369 A5.2**1.69010.04**10394699NM_009072**Rock2**Rho-associated coiled-coil containing protein kinase 212 A3**1.68980.0376**10354085NM_019570**Rev1**REV1 homolog (S. cerevisiae)1 B**1.68490.0097**10462922NM_019588**Plce1**phospholipase C, epsilon 119 D1**1.68290.032**10395259NM_021524**Nampt**nicotinamide phosphoribosyltransferase12 B1**1.6760.0284**10597875NM_010012**Cyp8b1**cytochrome P450, family 8, subfamily b, polypeptide 19 F4\|9 71.0 cM**1.67550.013**10344809NM_026493**Cspp1**centrosome and spindle pole associated protein 11 A2**1.67350.0484**10347748NM_028817**Acsl3**acyl-CoA synthetase long-chain family member 31 C4\|1 24.1 cM**1.67330.019**10375216NM_145962**Pank3**pantothenate kinase 311 A4**1.67330.013**10545877NM_023455**Nat8**N-acetyltransferase 8 (GCN5-related, putative)6 C3**1.66730.0378**10374453NM_008131**Glul**glutamate-ammonia ligase (glutamine synthetase)---**1.6660.0345**10515690NM_198170**Szt2**seizure threshold 24 D2.1**1.66010.0207**10591612NM_177030**Dock6**dedicator of cytokinesis 69 A3**1.65940.0225**10389214NM_011338**Ccl9**chemokine (C-C motif) ligand 911 C\|11 47.4 cM**1.65640.0355**10587688---**---**------**1.65540.0277**10595620---**---**------**1.65540.0277**10366275---**---**------**1.64810.0095**10607089NM_207625**Acsl4**acyl-CoA synthetase long-chain family member 4X F2**1.6470.0484**10379820NM_133360**Acaca**acetyl-Coenzyme A carboxylase alpha11 C**1.64520.0014**10414537NM_001161731**Ang**angiogenin, ribonuclease, RNase A family, 514 B-C1\|14 18.0 cM**1.64060.0094**10505779NM_139306**Acer2**alkaline ceramidase 24 C4**1.64030.0141**10564183AF241256**Snord116**small nucleolar RNA, C/D box 116 cluster7 C\|7 29.0 cM**1.63930.0126**10544573NM_027852**Rarres2**retinoic acid receptor responder (tazarotene induced) 26 B2.3**1.61740.0361**10472436NM_020283**B3galt1**UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 12 C3**1.61680.0376**10515399NM_013807**Plk3**polo-like kinase 3 (Drosophila)4 D1**1.6160.039**10407876NM_138654**5033411D12Rik**RIKEN cDNA 5033411D12 gene13 A2**1.61080.0317**10478847NM_001081005**1500012F01Rik**RIKEN cDNA 1500012F01 gene2 H3**1.60770.0445**10362896NM_009846**Cd24a**CD24a antigen10 B2\|10 26.0 cM**1.60590.0272**10535956NM_001163493**Stard13**StAR-related lipid transfer (START) domain containing 135 G3**1.60250.0225**10371400NM_007771**Cry1**cryptochrome 1 (photolyase-like)10 C\|10 46.0 cM**1.59890.0109**10540122NM_009320**Slc6a6**solute carrier family 6 (neurotransmitter transporter, taurine), member 66 D1\|6 38.2 cM**1.59370.0136**10580953---**---**------**1.59130.0232**10356082NM_011636**Plscr1**phospholipid scramblase 19 E3.3**1.58990.036**10453272NM_001001806**Zfp36l2**zinc finger protein 36, C3H type-like 217 E4**1.58970.013**10488322NM_001033348**Ralgapa2**Ral GTPase activating protein, alpha subunit 2 (catalytic)2 G1**1.58850.0019**10462406NM_001081319**C030046E11Rik**RIKEN cDNA C030046E11 gene19 C1**1.58580.0471**10382797NM_176902**Fam100b**family with sequence similarity 100, member B11 E2**1.5830.023**10346328XR_031547**Gm8292**predicted gene 82921 C1.2**1.58280.0066**10459766NR_028560**Scarna17**small Cajal body-specific RNA 1718\|18**1.58130.0232**10461642NR_028560**Scarna17**small Cajal body-specific RNA 1718\|18**1.58130.0232**10474545NM_133649**Slc12a6**solute carrier family 12, member 62 E3**1.58120.0361**10471503BC110660**Taf1d**TATA box binding protein (Tbp)-associated factor, RNA polymerase I, D9 A3**1.57970.0352**10572865NM_027837**Isx**intestine specific homeobox8 C2**1.57760.0224**10357345NM_172484**Nckap5**NCK-associated protein 51 E3**1.57260.0374**10501494NM_001042711**Amy2a5**amylase 2a53 F3\|3 50.0 cM**1.57150.015**10558295ENSMUST00000106157**Zranb1**zinc finger, RAN-binding domain containing 17 F3**1.56990.0362**10553829NR_003376**Gm7367**1110014K08Rik pseudogene7 C\|7**1.56630.0376**10553831NR_003376**Gm7367**1110014K08Rik pseudogene7 C\|7**1.56630.0376**10557233NM_144925**Tnrc6a**trinucleotide repeat containing 6a7 F3**1.56440.0447**10439667NM_145389**BC016579**cDNA sequence, BC01657916 B5**1.56330.0355**10354168NM_018775**Tbc1d8**TBC1 domain family, member 81 B**1.56030.0205**10418169ENSMUST00000079800 // ENSMUST00000079800**1700054O19Rik // 1700054O19Rik**RIKEN cDNA 1700054O19 gene // RIKEN cDNA 1700054O19 gene14 A3 // 14 A3**1.55390.0023**10509063NM_178257**Il22ra1**interleukin 22 receptor, alpha 14 D3\|4 62.0 cM**1.54660.0232**10391732NM_001159492**Gpatch8**G patch domain containing 811 E1**1.54210.0168**10399198NM_019744**Ncoa4**nuclear receptor coactivator 414 B**1.54120.0444**10512774NM_178893**Coro2a**coronin, actin binding protein 2A4 B1**1.53930.0307**10485633ENSMUST00000099651**Gm10796**predicted gene 10796---**1.53660.0286**10350758AK080751**A930039A15Rik**RIKEN cDNA A930039A15 gene---**1.53610.044**10427461NM_001136079**Ptger4**prostaglandin E receptor 4 (subtype EP4)15 A1\|15 6.4 cM**1.53410.0233**10417887NM_029104**Zmynd17**zinc finger, MYND domain containing 1714 B**1.5310.0494**10436209NM_001033238**Cblb**Casitas B-lineage lymphoma b16 B5**1.52870.0345**10587792NM_011636**Plscr1**phospholipid scramblase 19 E3.3**1.52750.0242**10469300NM_177268**Ankrd16**ankyrin repeat domain 162 A1**1.52310.0313**10497487---**---**------**1.52170.0217**10510286NM_027985**Mad2l2**MAD2 mitotic arrest deficient-like 2 (yeast)4 E1**1.520.0152**10475866NM_207680**Bcl2l11**BCL2-like 11 (apoptosis facilitator)2 F3-G1**1.51870.0194**10497421NM_080634**Hps3**Hermansky-Pudlak syndrome 3 homolog (human)3 A2\|3 12.5 cM**1.51530.0272**10538356NM_001163640**Chn2**chimerin (chimaerin) 26 B3**1.51420.0215**10475946NM_178404**Zc3h6**zinc finger CCCH type containing 62 F1**1.51390.0465**10584350NM_009429**Tpt1**tumor protein, translationally-controlled 114 D3**1.51340.0362**10523856---**---**------**1.51310.0416**10564159AF241256**Snord116**small nucleolar RNA, C/D box 116 cluster7 C\|7 29.0 cM**1.51260.0148**10559916---**---**------**1.50730.0309**10410513NM_001040692**Slc6a18**solute carrier family 6 (neurotransmitter transporter), member 1813 C1\|13 42.0 cM**1.5060.0469**10413839NM_001033988**Ncoa4**nuclear receptor coactivator 414 B**1.50540.048**10459768---**---**------**1.50050.0316**10562234NM_001110252**Hpn**hepsin7 B1**1.49720.0454**10407370NM_001113550**4833420G17Rik**RIKEN cDNA 4833420G17 gene13 D2.3**1.49540.0245**10517703---**---**------**1.49480.0146**10497441NM_013755**Gyg**glycogenin3 A2\|3 12.5 cM**1.48930.0056**10470959NM_172267**Phyhd1**phytanoyl-CoA dioxygenase domain containing 12 B**1.48910.0376**10601755NM_019865**Rpl36a**ribosomal protein L36AX E3**1.48750.0384**10355050NM_001045513**Raph1**Ras association (RalGDS/AF-6) and pleckstrin homology domains 11 C2**1.48430.0308**10514500NM_001004141**Cyp2j11**cytochrome P450, family 2, subfamily j, polypeptide 114 C5**1.4830.045**10497399NM_001122759**Pde7a**phosphodiesterase 7A3 A2\|3 7.0 cM**1.46970.0106**10532040NM_026856**Zfp644**zinc finger protein 6445 E5\|5 56.0 cM**1.46740.0484**10421972NM_019865**Rpl36a**ribosomal protein L36AX E3**1.4670.0489**10399478NM_015763**Lpin1**lipin 112 A1.1\|12 9.0 cM**1.46650.0214**10438358NM_213614**5-Sep**septin 516 A3\|16 11.42 cM**1.46540.0468**10544219NM_139294**Braf**Braf transforming gene6 B1\|6 15.5 cM**1.46390.0078**10358894NM_146126**Sord**sorbitol dehydrogenase2 E5\|2 66.0 cM**1.46180.0277**10401997NM_011877**Ptpn21**protein tyrosine phosphatase, non-receptor type 2112 F1**1.46160.0405**10475437NM_146126**Sord**sorbitol dehydrogenase2 E5\|2 66.0 cM**1.45990.0325**10379034NM_026708**Tlcd1**TLC domain containing 111 B5**1.45160.0339**10497935---**---**------**1.44540.0361**10389025NM_177390**Myo1d**myosin ID11 B5\|11 46.0 cM**1.4430.0454**10389022NM_177390**Myo1d**myosin ID11 B5\|11 46.0 cM**1.44280.0447**10396956NM_018814**Pcnx**pecanex homolog (Drosophila)12 D1**1.43860.0122**10462346NM_021525**Rcl1**RNA terminal phosphate cyclase-like 119 C1**1.43590.0151**10352416NM_130890**Capn8**calpain 81 H4**1.43170.0233**10592001NM_011176**St14**suppression of tumorigenicity 14 (colon carcinoma)9 A4\|9 17.0 cM**1.42890.0123**10507110---**---**------**1.42640.0448**10552030NM_008085**Gapdhs**glyceraldehyde-3-phosphate dehydrogenase, spermatogenic7 B1**1.41620.0437**10447429ENSMUST00000072072**Gm4832**predicted gene 483217 E4**1.41370.035**10520371NM_028234**Rbm33**RNA binding motif protein 335 B1**1.41170.045**10402117NM_153587**Rps6ka5**ribosomal protein S6 kinase, polypeptide 512 E**1.40720.048**10481827NM_001085507**Zbtb34**zinc finger and BTB domain containing 342 B**1.40710.0194**10526656NM_146164**Lrch4**leucine-rich repeats and calponin homology (CH) domain containing 45 G2**1.4040.0447**10582811NM_001164598**Irf2bp2**interferon regulatory factor 2 binding protein 28 E2**1.39430.0286**10493343---**---**------**1.39260.0441**10474725NM_013719**Eif2ak4**eukaryotic translation initiation factor 2 alpha kinase 4---**1.38740.0301**10489377NM_012032**Serinc3**serine incorporator 32 H3**1.37840.0274**10480570NM_001162485**Arrdc1**arrestin domain containing 12 A3**1.37340.0478**10366446NM_146010**Tspan8**tetraspanin 810 D2**1.37330.0324**10346970NM_011086**Pikfyve**phosphoinositide kinase, FYVE finger containing1 C2**1.37110.0175**10384423NM_172496**Cobl**cordon-bleu11 A1\|11 6.5 cM**1.37080.048**10476443NM_013829**Plcb4**phospholipase C, beta 42 F3\|2 77.0 cM**1.37050.0333**10534889NM_178162**Agfg2**ArfGAP with FG repeats 25 G2**1.3690.0181**10518428NM_011929**Clcn6**chloride channel 64 76.4 cM**1.36810.0262**10542264NM_001163445**2700089E24Rik**RIKEN cDNA 2700089E24 gene6 G1**1.36770.045**10497485---**---**------**1.36620.0333**10349065NM_001122676**Zcchc2**zinc finger, CCHC domain containing 21 E2.1**1.36030.0286**10477311NM_001039939**Asxl1**additional sex combs like 1 (Drosophila)2 H1**1.35920.0395**10432122NM_001170711**Asb8**ankyrin repeat and SOCS box-containing 815 F2**1.35040.0362**10567229NM_001031814**Smg1**SMG1 homolog, phosphatidylinositol 3-kinase-related kinase (C. elegans)7 F2**1.34810.0485**10376312NM_028451**Larp1**La ribonucleoprotein domain family, member 111 B2**1.33750.0311**10503161NM_001081417**Chd7**chromodomain helicase DNA binding protein 74 A1\|4 1.0 cM**1.33120.0407**10587150NM_001081322**Myo5c**myosin VC9 D**1.31330.0489**10476033NM_183262**Stk35**serine/threonine kinase 352 F1**1.29470.0412**10466530NM_001163144**Pcsk5**proprotein convertase subtilisin/kexin type 519 B\|19 18.0 cM**1.28940.0362**10478219NM_021280**Plcg1**phospholipase C, gamma 12 H2\|2 92.0 cM**1.27080.0381**10367919NM_029075**Stx11**syntaxin 1110 A1**−1.27940.048**10605319NM_145405**Ubl4**ubiquitin-like 4X A7.3\|X 29.9 cM**−1.28950.048**10508089NM_025544**Mrps15**mitochondrial ribosomal protein S154 D2.1**−1.29590.0479**10591482NM_016679**Keap1**kelch-like ECH-associated protein 19 A3**−1.2980.0397**10591739NM_001102404**Acp5**acid phosphatase 5, tartrate resistant9 A3\|9 6.0 cM**−1.30070.0272**10551159XR_034166**Gm4607**predicted gene 46077 A3\|7**−1.30160.0479**10413222NM_134084**Ppif**peptidylprolyl isomerase F (cyclophilin F)14 A3**−1.30370.048**10356657NM_024197**Ndufa10**NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 101 D**−1.30550.0479**10347672NM_027886**Stk11ip**serine/threonine kinase 11 interacting protein1 C3**−1.30590.0438**10439695NM_019754**Tagln3**transgelin 316 B5**−1.30870.0387**10593591NM_144784**Acat1**acetyl-Coenzyme A acetyltransferase 19 30.0 cM**−1.31150.0418**10432866NM_001003667**Krt77**keratin 7715 F3**−1.31410.0484**10378443NM_001011851**Olfr412**olfactory receptor 41211 B5**−1.31650.048**10487629NM_130884**Idh3b**isocitrate dehydrogenase 3 (NAD+) beta2 F3**−1.32140.0265**10432636NM_174992**Smagp**small cell adhesion glycoprotein15 F1**−1.32210.0376**10543684NR_030713**Mir183**microRNA 183---**−1.32470.0355**10411156NM_029153**Scamp1**secretory carrier membrane protein 113 D1**−1.32840.036**10585417NM_029573**Idh3a**isocitrate dehydrogenase 3 (NAD+) alpha9 A5.3**−1.33570.0367**10415742NM_027436**Mipep**mitochondrial intermediate peptidase14 D1**−1.33680.0307**10406205NM_030711**Erap1**endoplasmic reticulum aminopeptidase 113 C1**−1.34420.0454**10449940NM_022434**Cyp4f14**cytochrome P450, family 4, subfamily f, polypeptide 1417 B1**−1.34790.0363**10420225NM_010780**Cma1**chymase 1, mast cell14 C3\|14 20.0 cM**−1.35160.0307**10390685NM_025661**Ormdl3**ORM1-like 3 (S. cerevisiae)11 D**−1.35220.0445**10484431NM_025868**Tmx2**thioredoxin-related transmembrane protein 22 D**−1.35360.0486**10515930BC076608**AA415398**expressed sequence AA4153984 D2.1**−1.35750.0362**10607643---**---**------**−1.35790.0374**10386416NM_001011789**Olfr222**olfactory receptor 22211 B1.3**−1.35960.0447**10488291NM_015754**Rbbp9**retinoblastoma binding protein 92 G1-H1**−1.36170.032**10447551NM_027457**5730437N04Rik**RIKEN cDNA 5730437N04 gene17 A1**−1.36870.0396**10464128NM_007611**Casp7**caspase 719 D2\|19 50.0 cM**−1.36990.0383**10377286NM_001081566**Pik3r6**phosphoinositide-3-kinase, regulatory subunit 611 B3**−1.37310.0233**10539472NM_019542**Nagk**N-acetylglucosamine kinase6 D1**−1.37360.0143**10434191NM_013711**Txnrd2**thioredoxin reductase 216 A3\|16 11.2 cM**−1.37970.0324**10369525BC024943**2010107G23Rik**RIKEN cDNA 2010107G23 gene10 B4**−1.38150.0461**10465826NM_001160356**AI462493**expressed sequence AI46249319 A**−1.38690.0399**10435617NM_001042499**Rabl3**RAB, member of RAS oncogene family-like 316 B3**−1.39240.0387**10495285NM_019972**Sort1**sortilin 13 F3**−1.39320.035**10447354NM_025868**Tmx2**thioredoxin-related transmembrane protein 22 D**−1.39530.0338**10575894NM_026648**Lrrc50**leucine rich repeat containing 508 E1**−1.39880.0418**10368893NM_145743**Lace1**lactation elevated 110 B2\|10 25.5 cM**−1.3990.0265**10470050NM_007379**Abca2**ATP-binding cassette, sub-family A (ABC1), member 22 A2-B\|2 12.6 cM**−1.40230.0316**10566618NM_206897**Olfr6**olfactory receptor 67 E3**−1.40570.0416**10526514NM_021719**Cldn15**claudin 155 G2**−1.40770.0418**10483679NM_001080707**Gpr155**G protein-coupled receptor 1552 C3**−1.40790.035**10476301NM_001177833**Smox**spermine oxidase2 F1**−1.4080.0478**10365116NM_133964**Dohh**deoxyhypusine hydroxylase/monooxygenase10 C1**−1.42030.0304**10386086NM_153079**Nmur2**neuromedin U receptor 211 B1.3**−1.42890.043**10442370NM_019910**Dcpp1**demilune cell and parotid protein 117 A3.3\|17 10.0 cM**−1.43570.043**10593169NM_023114**Apoc3**apolipoprotein C-III9 A5.2\|9 27.0 cM**−1.43590.0317**10579508NM_001164679**Ano8**anoctamin 88 B3.3**−1.43750.015**10431300NM_001142357**Alg12**asparagine-linked glycosylation 12 homolog (yeast, alpha-1,6-mannosyltransferase)15 E3**−1.43890.0334**10585874NM_010421**Hexa**hexosaminidase A9 B\|9 29.0 cM**−1.43940.0245**10571302NM_026432**Tmem66**transmembrane protein 668 A4**−1.44120.0307**10519652NR_003596**Gm6455**predicted gene 64555 A1**−1.44550.0286**10397975NM_026790**Ifi27l1**interferon, alpha-inducible protein 27 like 112 E\|12 51.0 cM**−1.45070.0331**10362904NM_130892**Rtn4ip1**reticulon 4 interacting protein 110 B2\|10 29.0 cM**−1.45530.047**10352767NM_010892**Nek2**NIMA (never in mitosis gene a)-related expressed kinase 21 H6\|1 103.0 cM**−1.45550.0145**10480699NM_031843**Dpp7**dipeptidylpeptidase 72 A3**−1.45660.0363**10529454ENSMUST00000069741**E130018O15Rik**RIKEN cDNA E130018O15 gene5 B3**−1.46830.0429**10600531---**---**------**−1.46950.0218**10426812NM_010271**Gpd1**glycerol-3-phosphate dehydrogenase 1 (soluble)15 56.8 cM**−1.47460.0375**10519688NR_003596**Gm6455**predicted gene 64555 A1**−1.48040.0063**10518679NM_133435**Nmnat1**nicotinamide nucleotide adenylyltransferase 14 E2**−1.48140.048**10357418NM_001081078**Lct**lactase1 E4**−1.49020.0333**10559590NM_207270**Ptprh**protein tyrosine phosphatase, receptor type, H7 A1**−1.4940.0286**10525365NM_001042489**Hvcn1**hydrogen voltage-gated channel 15 F**−1.49440.0376**10424929NM_172960**Adck5**aarF domain containing kinase 515 D3**−1.49640.043**10351473NM_001033499**Sh2d1b2**SH2 domain protein 1B21 H3**−1.49880.0061**10547976NM_145391**Tapbpl**TAP binding protein-like6 F3**−1.50130.041**10521391NM_030721**Acox3**acyl-Coenzyme A oxidase 3, pristanoyl---**−1.50340.0098**10490104NM_011497**Aurka**aurora kinase A2 H3\|2 100.0 cM**−1.50770.035**10411633NM_008670**Naip1**NLR family, apoptosis inhibitory protein 113 D1-D3\|13 54.0 cM**−1.50780.0232**10450145NM_013585**Psmb9**proteasome (prosome, macropain) subunit, beta type 9 (large multifunctional peptidase 2)17 B1\|17 18.59 cM**−1.51670.045**10524681NM_026933**Triap1**TP53 regulated inhibitor of apoptosis 15 F**−1.5170.0058**10490491NM_008093**Gata5**GATA binding protein 52 H4\|2 106.0 cM**−1.51740.0361**10437655NM_011955**Nubp1**nucleotide binding protein 116 A1\|16 3.4 cM**−1.52170.0461**10441530NM_031395**Sytl3**synaptotagmin-like 317 A1**−1.52490.0443**10562130NM_194057**Ffar1**free fatty acid receptor 17 B1**−1.5260.0014**10463704NM_020577**As3mt**arsenic (+3 oxidation state) methyltransferase19 D1**−1.53570.0162**10524878NM_001033311**Vsig10**V-set and immunoglobulin domain containing 105 F**−1.54040.0046**10393573NM_011150**Lgals3bp**lectin, galactoside-binding, soluble, 3 binding protein11 E**−1.54060.0119**10606714NM_013463**Gla**galactosidase, alphaX E-F1\|X 53.0 cM**−1.54280.0277**10458547NR_028061**Gm8615**glucosamine-6-phosphate deaminase 1 pseudogene5 G3**−1.54510.0246**10384378NM_016672**Ddc**dopa decarboxylase11 A1-A4\|11 7.0 cM**−1.54720.043**10429638XR_032493**Gm9568**glyceraldehyde-3-phosphate dehydrogenase pseudogene15 D3\|15**−1.55020.0482**10510516NM_019741**Slc2a5**solute carrier family 2 (facilitated glucose transporter), member 54 E2**−1.55550.0065**10565634NM_008663**Myo7a**myosin VIIA7 E2\|7 48.1 cM**−1.57180.0053**10524422NM_010018**Dao**D-amino acid oxidase5 F\|5 65.0 cM**−1.5750.0418**10566583AK172683**Gm8995**predicted gene 89957 E3**−1.57890.0371**10391207NM_030150**Dhx58**DEXH (Asp-Glu-X-His) box polypeptide 5811 D\|11 61.5 cM**−1.57970.0135**10408879NM_001033399**Gfod1**glucose-fructose oxidoreductase domain containing 113 A4**−1.58470.013**10505954NM_013690**Tek**endothelial-specific receptor tyrosine kinase4 C5\|4 43.6 cM**−1.58770.0422**10538082NM_133764**Atp6v0e2**ATPase, H+ transporting, lysosomal V0 subunit E26 B3**−1.59180.0041**10545958NM_013471**Anxa4**annexin A46 D1\|6 38.0 cM**−1.5960.0411**10560474NM_177691**Ppm1n**protein phosphatase, Mg2+/Mn2+ dependent, 1N (putative)7 A3**−1.60660.0158**10577792NM_031257**Plekha2**pleckstrin homology domain-containing, family A (phosphoinositide binding specific) member 28 A2**−1.6230.0343**10455784NM_026240**Gramd3**GRAM domain containing 318 D2**−1.62380.0361**10467907NM_145502**Erlin1**ER lipid raft associated 119 C3**−1.62740.0115**10492102NM_144895**Spg20**spastic paraplegia 20, spartin (Troyer syndrome) homolog (human)3 C**−1.63170.0301**10377927NM_027445**Rnf167**ring finger protein 16711 B4**−1.6330.0209**10404439NM_011452**Serpinb9b**serine (or cysteine) peptidase inhibitor, clade B, member 9b13 A3.3\|13 12.5 cM**−1.63460.0217**10566585ENSMUST00000098144**Gm1966**predicted gene 19667 E3**−1.63870.0248**10587873---**---**------**−1.64460.037**10439068NM_145932**Osta**organic solute transporter alpha16 B3**−1.64480.035**10376726NM_001172112**Dhrs7b**dehydrogenase/reductase (SDR family) member 7B11 B2**−1.64760.0062**10469951NM_176834**Rnf208**ring finger protein 2082 A3**−1.64910.0225**10548817NM_025806**Plbd1**phospholipase B domain containing 16 G1**−1.6540.0163**10473356NM_019949**Ube2l6**ubiquitin-conjugating enzyme E2L 62 E1**−1.65440.0048**10501235NM_026764**Gstm4**glutathione S-transferase, mu 43 F2.3**−1.66220.0309**10474825NM_026412**D2Ertd750e**DNA segment, Chr 2, ERATO Doi 750, expressed2 E5**−1.67570.0095**10463716NM_033569**Cnnm2**cyclin M219 C3\|19 47.0 cM**−1.67970.0023**10604337---**---**------**−1.67980.0307**10595081NM_012033**Tinag**tubulointerstitial nephritis antigen9 D**−1.68280.0065**10524621NM_011854**Oasl2**2\'-5\' oligoadenylate synthetase-like 25 F**−1.6870.0489**10444810ENSMUST00000105041**H2-Q1**histocompatibility 2, Q region locus 117 B1\|17 19.14 cM**−1.68830.0032**10584334NM_011734**Siae**sialic acid acetylesterase9 A4\|9 19.0 cM**−1.6990.0032**10582985NM_009807**Casp1**caspase 19 A1\|9 1.0 cM**−1.69910.0091**10488185NM_009751**Bfsp1**beaded filament structural protein 1, in lens-CP942 G**−1.70140.0096**10491091NM_009425**Tnfsf10**tumor necrosis factor (ligand) superfamily, member 103 A3**−1.71310.0053**10583920NM_026189**Eepd1**endonuclease/exonuclease/phosphatase family domain containing 19 A4**−1.74180.0179**10378572NM_027249**Tlcd2**TLC domain containing 211 B5**−1.74990.0309**10383192---**---**------**−1.76770.0205**10559606NM_023440**Tmem86b**transmembrane protein 86B7 A1**−1.7760.008**10550740NM_027839**Ceacam20**carcinoembryonic antigen-related cell adhesion molecule 207 A3**−1.78370.0219**10486172NM_001033136**Fam82a2**family with sequence similarity 82, member A22 E5**−1.79110.0045**10482802NM_139200**Cytip**cytohesin 1 interacting protein2 C1.1**−1.7980.0078**10402347NM_029803**Ifi27l2a**interferon, alpha-inducible protein 27 like 2A12 E**−1.8070.0173**10519196NM_147776**Vwa1**von Willebrand factor A domain containing 1---**−1.80750.0079**10488636NM_001039120**Defb26**defensin beta 262 H1**−1.81030.041**10542857NM_178797**Far2**fatty acyl CoA reductase 26 G3**−1.82730.0308**10376832NM_007413**Adora2b**adenosine A2b receptor11 B2**−1.82820.0194**10558265NM_029609**Lhpp**phospholysine phosphohistidine inorganic pyrophosphate phosphatase7 F4**−1.82960.001**10569203NM_001142681**Chid1**chitinase domain containing 17 F5**−1.84680.0112**10571984NM_001081215**Ddx60**DEAD (Asp-Glu-Ala-Asp) box polypeptide 608 B3.1**−1.88050.05**10424221NM_001081396**Wdr67**WD repeat domain 6715 D1**−1.88790.0054**10364134NM_133184**Slc5a4a**solute carrier family 5, member 4a10 C1**−1.92640.0251**10447904NM_199252**Unc93a**unc-93 homolog A (C. elegans)17 A1\|17 7.8 cM**−1.92950.025**10539186NM_011259**Reg3a**regenerating islet-derived 3 alpha6 C3\|6 33.5 cM**−1.93550.0286**10451287NM_015783**Isg15**ISG15 ubiquitin-like modifier4 E2\|4**−1.9360.013**10447634NM_001142539**Gm9992**predicted gene 999217 A1**−1.95240.0175**10389261NM_001037932**Gm11437**predicted gene 1143711 C**−1.98320.0076**10538590NM_025992**Herc5**hect domain and RLD 56 C1\|6**−1.98830.0089**10510532NM_001085529**Slc2a7**solute carrier family 2 (facilitated glucose transporter), member 74 E2\|4**−2.00530.0136**10385500NM_008326**Irgm1**immunity-related GTPase family M member 111 B1.2**−2.01840.0234**10587871NM_198414**Paqr9**progestin and adipoQ receptor family member IX9 E3.3**−2.02070.0376**10568568NM_016978**Oat**ornithine aminotransferase7 F3\|7 63.0 cM**−2.04713.00E−04**10467470NM_019698**Aldh18a1**aldehyde dehydrogenase 18 family, member A119 C3**−2.37750.0079**10425287NM_134090**Kdelr3**KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 315 E1**−2.43350.0115**10376324NM_001135115**Gm12250**predicted gene 1225011 B1.3**−2.44770.0311**10443869NM_024442**Cyp4f16**cytochrome P450, family 4, subfamily f, polypeptide 1617 B1**−2.52180.0265**10566571NR_030719**Gm8979**very large inducible GTPase 1 pseudogene7 E3**−2.61980.0145**10390748NM_172564**Tns4**tensin 411 D**−2.62770.0044**10462618NM_010501**Ifit3**interferon-induced protein with tetratricopeptide repeats 319 C3**−2.62780.0357**10545200ENSMUST00000101325**LOC100046894**similar to Igk-C protein---**−2.64770.0473**10499899NM_009264**Sprr1a**small proline-rich protein 1A3 F1\|3 45.2 cM**−2.79720.0286**10483074NM_008100**Gcg**glucagon2 C1.3\|2 36.0 cM**−2.79770.0019**10557300NM_007474**Aqp8**aquaporin 87 F3\|7 61.0 cM**−2.79858.00E−04**10566578NR_030719**Gm8979**very large inducible GTPase 1 pseudogene7 E3**−2.80660.0095**10430006NM_028064**Slc39a4**solute carrier family 39 (zinc transporter), member 415 D3**−2.81880.0145**10390691NM_145434**Nr1d1**nuclear receptor subfamily 1, group D, member 111 D**−3.2983.00E−04**10480633NM_080854**Slc34a3**solute carrier family 34 (sodium phosphate), member 32 A3**−3.36140.013**10566366NM_199146**AI451617**expressed sequence AI4516177 E3**−3.92790.0019**10505451NM_011016**Orm2**orosomucoid 24 C1\|4 31.4 cM**3.97550.0307**10416057NM_013492**Clu**clusterin14 D1\|14 28.0 cM**3.64830.0393**10452854NM_053188**Srd5a2**steroid 5 alpha-reductase 217 E2**3.41677.00E−04**10367045NM_009040**Rdh16**retinol dehydrogenase 1610 D3**2.39840.0273**10523717NM_009263**Spp1**secreted phosphoprotein 15 E5\|5 56.0 cM**2.29850.0406**10464594BC034269**BC021614**cDNA sequence BC02161419 A**2.25810.011**10429140NM_008681**Ndrg1**N-myc downstream regulated gene 115 D2**2.0870.0273**10469609NR_033225**Gm13375**predicted gene 133752 A3**2.00480.0294**10507671NM_008190**Guca2a**guanylate cyclase activator 2a (guanylin)4 D2.1\|4 57.0 cM**1.89220.0482**10556113NM_016809**Rbm3**RNA binding motif protein 3X A1.1\|X 2.0 cM**1.81150.0271**10359917NM_010476**Hsd17b7**hydroxysteroid (17-beta) dehydrogenase 71 H3**1.76260.0467**10358454NM_001166409**Rbm3**RNA binding motif protein 3X A1.1\|X 2.0 cM**1.74440.0294**10540034NM_027406**Aldh1l1**aldehyde dehydrogenase 1 family, member L16 D1**1.71570.015**10371784NM_001163700**Nr1h4**nuclear receptor subfamily 1, group H, member 410 C2\|10 50.0 cM**1.70010.0435**10603469NM_001166409**Rbm3**RNA binding motif protein 3X A1.1\|X 2.0 cM**1.65790.0273**10582310NM_138656**Mvd**mevalonate (diphospho) decarboxylase8 E1**1.61790.0287**10518568---**---**------**1.54320.0336**10443898NM_134127**Cyp4f15**cytochrome P450, family 4, subfamily f, polypeptide 1517 B1**1.53110.0468**10344713NM_016661**Ahcy**S-adenosylhomocysteine hydrolase2 H1\|2 89.0 cM**1.52150.0425**10488816NM_016661**Ahcy**S-adenosylhomocysteine hydrolase2 H1\|2 89.0 cM**1.51270.0377**10439762NM_016661**Ahcy**S-adenosylhomocysteine hydrolase2 H1\|2 89.0 cM**1.50890.0468**10605055NM_028633**Haus7**HAUS augmin-like complex, subunit 7X A7.3**1.50830.015**10556169NM_025344**Eif3f**eukaryotic translation initiation factor 3, subunit F7 E3**1.4180.0317**10413542NM_009388**Tkt**transketolase14 B1**1.40430.0425**10408850NM_001111324**Nedd9**neural precursor cell expressed, developmentally down-regulated gene 913 A3.3-A4**−1.38530.0463**10489107NM_018851**Samhd1**SAM domain and HD domain, 12 H2**−1.41390.0456**10516620NM_010693**Lck**lymphocyte protein tyrosine kinase4 D2.2\|4 59.0 cM**−1.42590.0348**10513256NM_010336**Lpar1**lysophosphatidic acid receptor 14 B3\|4 16.0 cM**−1.4340.0294**10604057NR_033443**6-Sep**septin 6X A2**−1.45320.0468**10588464NR_029526**Mirlet7g**microRNA let7g---**−1.4640.0301**10432362NM_026967**Rhebl1**Ras homolog enriched in brain like 115 F2**−1.490.017**10350173NM_001130174**Tnnt2**troponin T2, cardiac1 E4\|1 60.0 cM**−1.49440.0425**10547906NM_008479**Lag3**lymphocyte-activation gene 36 F2**−1.51080.0346**10420659NM_025697**6330409N04Rik**RIKEN cDNA 6330409N04 gene14 D1**−1.54510.0354**10352097NM_027077**1700016C15Rik**RIKEN cDNA 1700016C15 gene1 H3**−1.55030.0468**10409579NM_019568**Cxcl14**chemokine (C-X-C motif) ligand 1413 B1**−1.57990.0377**10355960NM_009129**Scg2**secretogranin II1 C4\|1 43.6 cM**−1.60190.0178**10478633NM_013599**Mmp9**matrix metallopeptidase 92 H1-H2\|2 96.0 cM**−1.60690.0228**10501629NM_001080818**Cdc14a**CDC14 cell division cycle 14 homolog A (S. cerevisiae)3 G1**−1.62170.0425**10447056NM_027455**Qpct**glutaminyl-peptide cyclotransferase (glutaminyl cyclase)17 E3**−1.63260.0228**10407940---**---**------**−1.66810.0294**10605355---**---**------**−1.68260.0494**10593015NM_009850**Cd3g**CD3 antigen, gamma polypeptide9 A5.2\|9 26.0 cM**−1.68930.0161**10464999NM_028623**Cst6**cystatin E/M19 A\|19 4.0 cM**−1.72190.0456**10584821NM_013487**Cd3d**CD3 antigen, delta polypeptide9 A5.2\|9 26.0 cM**−1.73590.0435**10561927NM_007467**Aplp1**amyloid beta (A4) precursor-like protein 17 B1\|7 8.0 cM**−1.73670.0109**10552406NM_024253**Nkg7**natural killer cell group 7 sequence7 B2**−1.75010.0178**10366881NM_007837**Ddit3**DNA-damage inducible transcript 310 D3**−1.76210.0344**10490923NM_009801**Car2**carbonic anhydrase 23 A1\|3 10.5 cM**−1.77260.0189**10428534NM_032000**Trps1**trichorhinophalangeal syndrome I (human)15 C\|15 30.1 cM**−1.7930.0494**10403821ENSMUST00000103558**Tcrg-V3**T-cell receptor gamma, variable 3---**−1.82130.0468**10516093NM_007558**Bmp8a**bone morphogenetic protein 8a4 D2.2\|4 57.4 cM**−1.83920.0307**10513739NM_011607**Tnc**tenascin C4 C1\|4 32.2 cM**−1.8530.0348**10574166NM_153507**Cpne2**copine II8 C5**−1.8570.0346**10542632NM_010491**Iapp**islet amyloid polypeptide6 G2\|6 62.0 cM**−1.88270.0301**10541605NM_020001**Clec4n**C-type lectin domain family 4, member n6 F3\|6 55.0 cM**−1.8890.017**10402325NM_023049**Asb2**ankyrin repeat and SOCS box-containing 212 E\|12 50.0 cM**−1.90870.0492**10466200NM_027836**Ms4a7**membrane-spanning 4-domains, subfamily A, member 719 A**−1.93590.0172**10404913NM_026056**Cap2**CAP, adenylate cyclase-associated protein, 2 (yeast)13 A5**−1.96190.0346**10420308NM_013542**Gzmb**granzyme B14 D3\|14 20.5 cM**−1.97050.0294**10412211NM_010370**Gzma**granzyme A13 D\|13 64.0 cM**−2.01820.0229**10463016NM_028191**Cyp2c65**cytochrome P450, family 2, subfamily c, polypeptide 6519 C3**−2.12520.0456**10551197NM_009999**Cyp2b10**cytochrome P450, family 2, subfamily b, polypeptide 107 A3\|7 6.5 cM**−2.57530.0138**10512999NR_033139**AI427809**expressed sequence AI4278094 B2**−2.58060.0109**10405063NM_008760**Ogn**osteoglycin13 A5**−2.68780.0346**10512949NM_013454**Abca1**ATP-binding cassette, sub-family A (ABC1), member 14 A5-B3\|4 23.1 cM**−2.7530.0273**10366043NM_026268**Dusp6**dual specificity phosphatase 610 C3**−3.03690.0224**10534493NM_019577**Ccl24**chemokine (C-C motif) ligand 245 G1**−4.94740.0072**10463023NM_001011707**Cyp2c66**cytochrome P450, family 2, subfamily c, polypeptide 6619 C3**−5.0820.015**
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